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Background: Long-term follow-up on a clinical trial of 15 stage III-IV NSCLC patients
treated with an Indoleamine 2,3-Dioxygenase (IDO) peptide vaccine (NCT01219348).
Methods: Fifteen HLA-A2-positive patients with stable stage III-IV NSCLC after standard
chemotherapy were treated with subcutaneous vaccinations (100 µg IDO5 peptide,
sequence ALLEIASCL, formulated in 900 µl Montanide) biweekly for 2.5 months and
thereafter monthly until progression or up to 5 years. Here we report long-term clinical
follow-up, toxicity and immunity.
Results: Three of 15 patients are still alive corresponding to a 6-year overall survival of 20
%. Two patients continued monthly vaccinations for 5 years (56 vaccines). One of the two
patients developed a partial response (PR) of target lesions in the liver 15 months after the
first vaccine and has remained in PR ever since. The other patient had a solitary distant
metastasis in a lymph node in retroperitoneum at baseline which normalized during
treatment. All following evaluation scans during the treatment have been tumor free. The
vaccine was well tolerated for all 5 years with no long-term toxicities registered. The third
long-term surviving patient discontinued vaccinations after 11 months due to disease
progression. Flow cytometry analyses of PBMCs from the two long-term responders
demonstrated stable CD8+ and CD4+ T-cell populations during treatment. In addition,
presence of IDO-specific T-cells was detected by IFN-γ Elispot in both patients at several
time points during treatment.
Conclusion: IDO peptide vaccination was well tolerated for administration up to 5years.
Two of 15 patients are long-term responders with ongoing clinical response 6 years after
1st vaccination.
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INTRODUCTION
Lung cancer is the leading cause of cancer death in both men and
women worldwide, with non-small-cell lung cancer (NSCLC)
accounting for 85–90% (1). At the time of diagnosis most patients
have stage III–IV inoperable disease with a poor prognosis and a
5-year overall survival of <5%.
Previously, first-line standard treatment for the majority of
patients with metastatic NSCLC, when no targetable alteration
is revealed, was platinum-based chemotherapy, but only 15–30%
of the patients responded (2).
Cancer immunotherapy, a treatment that boosts the body’s
natural defense to fight cancer has greatly evolved the last
decade, and is now the standard of choice in many solid
tumors. Nivolumab and Pembrolizumab, both PD-1 blocking
antibodies and Atezolizumab a PD-L1 blocking antibody
are approved by FDA and EMA for second line treatment
for NSCLC and Pembrolizumab as first line treatment for
patients with tumors expressing PD-L1 (3–5). All three
antibodies work by relieving the suppression of the anti-
tumor immunity, thereby boosting the immune system to
kill cancer cells. Multiple immune regulatory targets are
being investigated these days, among others indoleamine 2,3-
dioxygenase (IDO).
IDO is an intracellular enzyme that catalyzes the rate-
limiting step in degradation of Tryptophan (T) leading to local
depletion and an increase in Kynurenine (K) metabolites (6).
An upregulation of IDO in tumor cells leads to depletion of
T which suppresses T-cell function and survival (7). Because
T and K concentration can be measured from patients’ serum,
IDO activity can be monitored by computing K/T ratio (8).
Consequently, cancer patients, including lung cancer, exhibit
higher K/T ratios compared to healthy donors suggesting
FIGURE 1 | Swimmer plot of the 15 stage III–IV HLA-A2+ NSCLC patients who received study drug (IDO peptide vaccine). Two of 15 patients are long-term
responders (as of 6 years after the 1st vaccine). Durable response is defined as >8.5 months clinical treatment benefit.
elevated IDO activity in cancer patients, thus proposing IDO as a
valuable target in cancer.
IDO-specific T-cells have been shown to influence adaptive
immune reactions in both cancer patients and healthy donors.
Further, we have shown that these IDO-specific T-cells are
cytotoxic effector cells capable of recognizing and killing both
cancer cells and immunosuppressive dendritic cells in vitro.
These findings justified clinical testing of an IDO derived peptide
vaccine with the aim of boosting the IDO specific cytotoxic T-
cells (9). A phase I vaccination study was performed at our
institution from 2010 to 2012 including 15 HLA-A2+ stage
III/IV NSCLC patients, demonstrating significant improved
overall survival when compared with the group of excluded
patients because of HLA-A2 negativity (10). Here, we present
the long-term clinical and immunological outcomes of the
treatment.
MATERIALS AND METHODS
Patients
Fifteen HLA-A2 positive patients with biopsy verified stage III–
IV NSCLC in stable disease after standard chemotherapy were
treated with subcutaneous vaccinations (100 µg IDO5 peptide,
sequence ALLEIASCL, formulated in 900 µl of the adjuvant
Montanide) (11). This study was carried out in accordance with
the recommendations of GCP with written informed consent
from all subjects. All subjects gave written informed consent
in accordance with the Declaration of Helsinki. The protocol
was approved by the National Board of Health and the local
Ethics Committee at the Capital Region of Denmark. The initial
study (NCT01219348) results have previously been reported
(10). Patients were enrolled from June 2010 to May 2012 and
treated every second week for 2.5 months and thereafter monthly
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FIGURE 2 | Elispot analysis of IDO-specific T-cells in consecutive blood
samples from long-term responders. IDO specific T-cells were demonstrated in
patient #17 and #18 at several time points during IDO vaccination course.
until progression or up to 5 years. Two of the 15 patients
have completed 5 years of vaccination, enabling evaluation of
potential long-term toxicity according to CTCAE version 4.0.
Furthermore, long-term clinical benefit was evaluated by CT or
PET-CT scans according to Response Evaluation Criteria in Solid
Tumors 1.1 (RECIST 1.1) at baseline and every third month for a
completion of 5 years follow-up.
Patient Material
Peripheral blood mononuclear cells (PBMC) were obtained
from peripheral blood by Lymphoprep technique by gradient
centrifugation every third month during vaccination from the
two long-term responders. Isolated cells were frozen immediately
with 90% humanized AB-serum and 10% dimethyl sulfoxide and
stored at−180◦C.
Elispot
To assess whether IDO vaccination resulted in measurable T-
cell responses in the two long-term patients, we performed
indirect IFN- ELISPOT as previously described. Briefly, PBMCs
were stimulated once in ex vivo medium +5% HS, 120 U/L
interleukin-2 and 15 umol/L IDO5 peptide prior to analysis to
extend the sensitivity of the assay. After 7 days in culture, cells
were counted and analyzed in IFN-y ELISPOT. Nitrocellular
bottomed 96-well plates (MultiScreen MAIP N45; Millipore)
were coated with IFN-y capture mAb (Mabtech) overnight.
Wells were washed, blocked by X-vivo medium and the effector
cells were added in duplicates at different concentrations with or
without 5 umol/L of the IDO5 peptide. Plates were incubated
overnight and medium was discharged and wells washed prior
to addition of biotinylated secondary Ab (Mabtech). Plates were
incubated at room temperature (RT) for 2 h, washed and avidin-
enzyme conjugate was added to each well. Plates were incubated
at RT for 1 h and the enzyme substrate NBT/BCIP (Invitrogen
Life Technologies) was added to each well and incubated at RT
for 5–10min. Upon the emergence of dark purple spots, the
reaction was terminated by washing with tap water. The spots
were counted using the ImmunoSpot Series 2.0 Analyzer (CTL
Analyzers).
Flow Cytometry
PBMC samples were thawed in 37◦C RPMI medium 1640 +
GlutaMAX (Life Technologies) and thereafter washed in RPMI
and stained in PBS containing 0.5% bovine serum albumin.
For phenotyping of CD3+ T-cells, the following antibodies
were used: CD45RA-FITC, CD62L-PE, CCR7-PE-CY7, CD3-
APC, CD8-BV421, CD4-HV510 (BD Biosciences), CD27-PerCP
(Nordic Biosite). Natural Killer cells, B-cells, and γ/δ cells were
stained with the following antibodies: CD16-FITC, CD56-PE,
CD19-PE-CY7, CD3-APC (BD Biosciences), and γ/δ -BV421
(Nordic Biosite). Myeloid derived suppressor cells were stained
with: CD33-FITC, HLA-DR-PerCP, lineage = CD3-, CD19-,
and CD56-PE-Cy7, CD11b-APC (BD Biosciences), CD14-BV421
(Nordic Biosite). Regulatory T-cells were stained with CD45RA-
FITC, CCR4-PerCP-Cy5.5, CD127-PE-Cy7, CD4-APC, CD25-
BV421 (BD Biosciences), FoxP3-PE (eBiosciences). Dead cell
marker APC-Cy7 near IR (Invitrogen) fluorescent reactive
dye was used to exclude dead cells. For intracellular staining
of transcription factor FoxP3, we used Transcription Factor
Staining Buffer set (eBioscience) according to guidelines issued
by the manufacturer.
RESULTS
Long-Term Clinical Follow-Up
Three of the 15 patients are still alive (as of May 2018)
corresponding to a 6-year overall survival of 20% (Figure 1).
One patient was excluded from the trial due to progression after
11 months; the two other patients continued to be on monthly
vaccination for 5 years with no other anti-cancer therapy given.
They each received a total of 56 vaccines. Both patients had IDO
expressing tumors (30–50%) by immunohistochemistry (10).
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FIGURE 3 | Percentage of NK cells, Treg cells, MDSCs, and CD8+ T cell subpopulations during IDO vaccination course.
One of the two long-term responders (#18) was diagnosed
with stage IV adenocarcinoma in 2009 (localized in lung and
liver) and was initially treated with 1st line Carboplatin and
Pemetrexed, 2nd line Erlotinib followed by 3rd line Docetaxel
before inclusion in the trial in 2012. The patient achieved a partial
response (PR) of target lesions in the liver 15months after the first
vaccine was administered and has been in ongoing stable PR for
6 years.
The other long-term responder (#17) was diagnosed with
stage III adenocarcinoma in 2009; initially treated with an
upper right lobectomy and subsequently 1. line Cisplatin and
Vinorelbine. Further dissemination lead to a left adrenalectomy
in 2010 due to a metastasis, followed 1 year later by 2.
line Cisplatin and Pemetrexed for retroperitoneal lymph node
recurrence before inclusion in the IDO vaccination trial in 2012.
The patient had a solitary metastasis in a retroperitoneal gland
(1.3 cm) at baseline which was normalized at 2nd evaluation
during IDO vaccination. Absence of recurrent disease have been
confirmed by CT ongoing for 6 years.
The third long-term survivor had stage IV disease and was
treated with 4 lines of therapy before trial inclusion. The patient
progressed after 11 months on IDO vaccination (14 vaccines
administered) and was referred to standard of care where
additional four lines of therapy have been given.
Long-Term Toxicity
The vaccine was well-tolerated in both long-term responders
receiving the vaccine for 5 years and no CTCAE grade 3–
4 adverse events were observed. Both patients are in good
performance status (PS 0) and only experienced grade 1 or 2
local reactions at the injection site; i.e., redness, itching, and
subcutaneous granuloma. All three local reactions are known
AEs to the adjuvant Montanide.
Long-Term Immunity
Consecutive ELISPOT analyses for evaluation of peripheral
blood immune reactivity to the IDO peptide were established
for the two long-term responders during their 5 years
of treatment. Immune-monitoring demonstrated detectable
vaccination-induced IDO specific T-cell responses at several
time-points during vaccination on the two patients as opposed
to baseline samples (Figure 2).
Consecutive flow cytometry analyses of PBMCs during
continuing vaccination (available from 8 to 56 months) were
also performed on the two long-term responders (Figure 3).
Peripheral blood percentages of CD8+ and CD4+ T-cells did not
change significantly during vaccination as well as subpopulations
of naïve, effector memory (EM), central memory and EMRA T-
cells. Additional FACS analyses of natural killer (NK) cells, CD4+
regulatory T cells (Tregs), and myeloid derived suppressor cells
(MDSCs) were also stable during vaccination for 5 years.
DISCUSSION
As published in 2013, vaccination in a phase I trial with an
epitope derived from IDO in 15 patients with disease stabilization
after standard chemotherapy demonstrated long-lasting PR+SD
of at least 8.5 months in 47% of the patients (10). Historically,
median PFS in patients with stage IV NSCLC treated with at least
one line of chemotherapy is ∼6–7 months (12). This long-term
follow-up 6 years after IDO vaccine initiation shows a 20% 6-
year overall survival as compared to historical data with a 5-year
OS <5%. The improved OS obviously needs confirmation in a
larger randomized clinical study. Still, two of 15 patients have
ongoing clinical response 6 years after vaccination initiation and
have not received additional anti-neoplastic treatment following
the vaccination period.
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Importantly, the two patients with ongoing clinical response
have received 56 vaccines in total over 5 years, with only local
and manageable side effects and no grade 3–4 toxicity reassuring
the vaccine to be safe for administration for a long period.
Many vaccine trials in NSCLC have shown a vaccination
induced immune response; usually an increase of target specific
cytotoxic T-cells as observed in our trial. Unfortunately, this
has not translated into significant survival advantages in phase
III trials to date testing antigenic target vaccines, whole cell
vaccines and vector based vaccines. In terms of toxicity,
all tested vaccines have shown less toxicity compared to
immune checkpoint inhibitors and chemotherapies (13–17).
The demonstration of enhanced immune response without
concomitant survival benefit suggests that vaccine therapy might
benefit from combination with other therapeutic modalities such
as checkpoint inhibitors, chemotherapy or radiation therapy.
Although the immune checkpoint inhibitors have shown
tremendous potential, response rates remain relatively low
in lung cancer. Two PD-1 inhibitors (Nivolumab and
Pembrolizumab) and one PD-L1 inhibitor (atezolizumab)
have been approved by FDA and EMA for 2nd line treatment
in NSCLC and Pembrolizumab for first line treatment in
patients whose tumors have high expression of PD-L1 (>50%).
Durvalumab, a PD-1 inhibitor, is approved by FDA for stage III
NSCLC patients post chemoradiotherapy (18). Tumor-associated
macrophages (TAM) and MDSCs play important roles in tumor
immune evasion and their presence in the tumor limit the
accumulation of T-cells. An understanding of IDO-reactive
T-cells may lead to a treatment strategy improving effectiveness
of checkpoint inhibition by activation of IDO specific T-cells
reacting toward both tumor- and regulatory cells at the tumor
site, thereby leading to local inflammation and diminished
immune inhibition.
We hypothesize that vaccine induced activated IDO-reactive
T-cells would attract T-cells into the tumor, resulting in
inflammation, inducing PD-L1 upregulation on cancer cells
as well as immune cells and thereby generating targets more
susceptible to anti-PD-1/PD-L1 immunotherapy.
We therefore suggest that combination of a PD-1 blocking
antibody and the IDO derived peptide vaccine potentially could
increase clinical benefit in patients with NSCLC. To this end,
a clinical phase I/II trial is running at our institution with the
combination of an IDO and PD-L1 derived peptide vaccine
in combination with Nivolumab for patients with metastatic
melanoma. Pre-clinical toxicity data show no additional
toxicity with the combination compared to Nivolumab alone
(NCT03047928).
Epacadostat an IDO inhibitor plus Pembrolizumab have been
tested in patients with NSCLC resulting in response rates up to
40–50% and with no additional toxicities in a phase I/II study
(19). Currently a phase III trial (ECHO-305/NCT03322540) is
running. However, Epacadostat and Pembrolizumab failed to
improve progression free survival compared to Pembrolizumab
alone in a phase III trial in patients with metastatic melanoma
(ECHO-301/KEYNOTE-252 trial). Extensive biomarker analyses
are being conducted to contribute to the understanding of the
failure.
Presently, a randomized phase II clinical trial is being initiated
in patients with NSCLC combining PD-1 blocking antibody and
this IDO derived peptide vaccine (Keynote-764).
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